Research and Clinical Trials

Brief Description  
A prospective open label study to evaluate the feasibility and safety of moleculary guided therapy in patients with with refractory or recurrent neuroblastoma.
Who may be Eligible  
Patients greater than 1 year to 21 years of age, diagnosed with relapsed or refractory neuroblastoma.
Speciality/Disorder  
Pediatric Cancer
IRB Number  
03-11-20b
Principal Investigator  
Kaplan, Joel

For More Information, Contact  Beatriz  G, Perez-Li
Phone:  (704) 446-5285  Fax:  (704) 355-1188  
Email:  beatriz.perezli@carolinashealthcare.org
Address:1025 Morehead Medical Drive Charlotte, NC
Close